By admin 
CureSearch for Children’s Cancer, a leading national non-profit foundation dedicated to ending childhood cancer by driving targeted and innovative research, has officially announced the appointment of Osama Alsaleh to its Board of Directors. A prominent figure in the global healthcare technology and venture capital sectors, Alsaleh joins the organization at a critical juncture in the fight against pediatric malignancies. His appointment is expected to bolster CureSearch’s strategic initiatives by leveraging his extensive background in venture capital partnerships, health equity, and large-scale technological integration. Currently serving as the Head of Partnerships at Plug and Play Health, Alsaleh brings a unique perspective that bridges the gap between early-stage clinical research and the commercial investment necessary to bring life-saving treatments to market.
The addition of Alsaleh to the board reflects a growing trend in the non-profit sector toward "venture philanthropy"—a model that applies the principles of venture capital to charitable giving to maximize impact and accelerate the development of new therapies. In his new role, Alsaleh will assist CureSearch in navigating the complex landscape of healthcare innovation, ensuring that pediatric oncology remains a priority for global investors and technology developers who often focus on the more lucrative adult oncology markets.
A Career Defined by Innovation and Health Equity
Osama Alsaleh’s professional trajectory has been marked by a consistent focus on systemic improvements within the healthcare industry. As the Head of Partnerships at Plug and Play Health, he oversees collaborations within one of the world’s most active venture capital firms and innovation platforms. Plug and Play is renowned for connecting startups with corporate giants, a role that has given Alsaleh deep insight into how emerging technologies can be scaled to solve global health challenges.
Before his tenure at Plug and Play, Alsaleh held several high-impact roles at Oracle Health (formerly Cerner Corporation). During his time there, he was instrumental in the formation of Oracle’s health equity team. This initiative was designed to address the social determinants of health—factors such as socioeconomic status, education, and geographic location that significantly influence patient outcomes. By shaping strategies for accessibility and inclusivity, Alsaleh helped ensure that technological advancements in healthcare reached underserved populations, a mission that aligns closely with CureSearch’s commitment to all children battling cancer.
Furthermore, Alsaleh’s experience with the Oracle Charitable Foundation Clinical Decision Committee saw him contributing to the evaluation and distribution of more than $42 million in healthcare grants. This experience provided him with a rigorous understanding of the grant-making process and the metrics required to measure the success of clinical initiatives. His career also includes significant stints at the World Bank Group and the World Health Organization (WHO), where he focused on sustainable global health solutions and strategic planning.
Navigating the Regulatory and Policy Landscape
Beyond the private sector, Alsaleh has been a frequent advisor on matters of public policy and regulatory compliance. His expertise has been sought by some of the most influential government bodies in the United States. He has collaborated on initiatives with the Centers for Medicare & Medicaid Services (CMS) regarding quality reporting measures and served as a consultant for the White House COVID-19 Task Force during the height of the global pandemic.
His work with the U.S. State Department further underscores his ability to convene leaders across different sectors to drive meaningful progress. This background in regulatory navigation is particularly valuable for CureSearch, as the path from laboratory research to FDA approval for pediatric drugs is fraught with unique challenges, including smaller patient populations for clinical trials and more stringent safety requirements for children.
The Critical Need for Pediatric Cancer Innovation
The appointment comes at a time when the pediatric oncology field faces a significant "innovation gap." While adult cancer research often receives massive infusions of capital from pharmaceutical companies and venture capitalists, pediatric cancer research remains chronically underfunded. According to data from the National Cancer Institute (NCI), only about 4% of federal funding for cancer research is directed toward pediatric cancers.
This disparity creates what researchers call the "Valley of Death," a stage where promising laboratory discoveries fail to transition into clinical trials because of a lack of financial backing. CureSearch specifically targets this gap by funding research that has a clear path to the clinic. By bringing in a board member with Alsaleh’s venture capital pedigree, the organization aims to attract more "non-traditional" funding sources and strategic partners to ensure that breakthrough discoveries do not stall due to lack of resources.
The statistics surrounding childhood cancer highlight the urgency of this mission. Cancer remains the leading cause of death by disease for children in the United States. While survival rates for some types of pediatric cancer, such as certain forms of leukemia, have improved significantly over the last few decades, others, such as diffuse intrinsic pontine glioma (DIPG), remain almost universally fatal. Moreover, many survivors face lifelong health challenges, including secondary cancers, heart disease, and cognitive impairments, due to the toxicity of current treatments—many of which were developed for adults and are decades old.
Leadership Perspectives on the Appointment
The leadership at CureSearch has expressed high expectations for the impact Alsaleh will have on the organization’s trajectory. Jared Brancazio, Chair of the CureSearch Board of Directors, emphasized the strategic importance of this appointment in a recent statement.
"Osama brings a unique and highly valuable perspective to CureSearch," Brancazio said. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer. We are excited to have him join the board at this important time for our organization."
For his part, Alsaleh has identified the underrepresentation of pediatrics in the innovation ecosystem as a primary motivator for his involvement. He noted that throughout his career in venture capital and technology, he has observed that pediatric-focused innovations are often sidelined in favor of adult markets.
"Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underfunded and underrepresented within mainstream venture capital and innovation ecosystems," Alsaleh stated. "By leveraging my network across venture capital, startups, healthcare institutions, and technology companies, I aim to help attract new technologies, strategic partners, and resources that can accelerate progress toward cures for children with cancer."
Analysis: The Strategic Impact of Venture-Minded Philanthropy
Industry analysts suggest that the recruitment of leaders like Alsaleh signals a shift in how major health non-profits operate. In an era where drug development costs can exceed $2 billion per new therapy, traditional fundraising alone is often insufficient to bring a new drug to market. By integrating board members who understand the mechanics of venture capital, organizations like CureSearch can better position their research portfolios to be "investment-ready."
This strategy involves not only providing initial grants but also helping researchers protect their intellectual property, form startup companies, and pitch to private investors. Alsaleh’s role at Plug and Play Health makes him uniquely qualified to facilitate these connections. If CureSearch can successfully bridge the gap between non-profit research and private sector scaling, it could significantly shorten the timeline for new treatments to reach pediatric patients.
Furthermore, Alsaleh’s focus on health equity is likely to influence CureSearch’s research priorities. Historically, clinical trials have often lacked diversity, leading to treatments that may not be equally effective across all demographic groups. With Alsaleh’s background in addressing social determinants of health, the board is expected to place a greater emphasis on ensuring that clinical trial access is expanded to include children from all backgrounds, regardless of their proximity to major academic medical centers.
A Timeline of CureSearch’s Evolution
The appointment of Osama Alsaleh is part of a broader evolution for CureSearch. Founded decades ago as a support network for clinical trials, the organization has pivoted in recent years to become a sophisticated engine for drug development.
- Early 2000s: CureSearch played a pivotal role in supporting the Children’s Oncology Group (COG), the world’s largest organization devoted to pediatric cancer research.
- 2010-2015: The organization shifted its focus toward the "acceleration" of research, launching the Catapult Award and the Young Investigator Award to fund high-impact, high-risk research.
- 2018-2022: CureSearch intensified its focus on the "Valley of Death," specifically seeking to fund projects that have the potential to move from the lab to a Phase I clinical trial within three years.
- 2024: With the appointment of Alsaleh, the organization signals a new phase of growth focused on global partnerships, venture capital integration, and technological innovation.
Future Outlook and Implications
As CureSearch continues to expand its influence, the integration of technology and data science will play an increasingly vital role. Modern oncology relies heavily on genomic sequencing, AI-driven drug discovery, and real-world evidence—all areas where Alsaleh’s expertise at Oracle and Plug and Play will be instrumental.
The pediatric oncology community is watching closely to see if this infusion of venture-style leadership can overcome the market failures that have historically slowed progress for children. If Alsaleh can successfully translate his success in the corporate and tech worlds to the non-profit sector, it may provide a blueprint for other disease-specific foundations looking to break through funding plateaus.
For the thousands of families currently navigating a pediatric cancer diagnosis, the appointment of a leader focused on "accelerating progress" is more than just a corporate update; it represents a tangible hope that the next generation of treatments is moving closer to reality. CureSearch’s mission to end children’s cancer is an ambitious one, but with a board that now includes experts in global innovation, venture capital, and health equity, the organization is better positioned than ever to turn that ambition into clinical results.
